Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo

Hepatocellular carcinoma (HCC) is the sixth most frequent malignant tumor with poor prognosis, and its clinical therapeutic outcome is poor. Volasertib, a potent small molecular inhibitor of polo-like kinase 1 (PLK1), is currently tested for treatment of multiple cancers in the clinical trials. Howe...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Cancer Res
Autori principali: Zheng, Di-Wei, Xue, You-Qiu, Li, Yong, Di, Jin-Ming, Qiu, Jian-Ge, Zhang, Wen-Ji, Jiang, Qi-Wei, Yang, Yang, Chen, Yao, Wei, Meng-Ning, Huang, Jia-Rong, Wang, Kun, Wei, Xing, Shi, Zhi
Natura: Artigo
Lingua:Inglês
Pubblicazione: e-Century Publishing Corporation 2016
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5126267/
https://ncbi.nlm.nih.gov/pubmed/27904765
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi